NMC Health Plc (NMC) is a healthcare service provider that offers medical and healthcare products and services. The group distributes pharmaceutical products, medical equipment, medical consumables & devices, consumer products, education & office supplies, veterinary products and rehab supplies.
Shares of NMC accelerated by more than 8% in the last five trading sessions, however on a monthly basis, shares were up by around 14 per cent.
On April 05, 2019, the board of NMC Health announced the appointment of Mr Tarek Alnabulsi as an independent director of the NMC Health Plc with an immediate effect of his role. Mr Alnabulsi is a businessman and founder and co-founder of many businesses based out in Saudi Arabia, UAE and USA and carrying an experience of more than 20 years with a leading group of Middle East.
Post announcement of the appointment of Mr Alnabulsi on April 05, shares of NMC Health Plc surged by 6.25%. However, on a yearly basis, shares have delivered a negative return of around 22% and on a year-to-date basis, the stock has delivered a negative return of 1.05%.
Stock Performance â 1 Year
Daily price chart (as on April 25, 2019), before the market close. (Source: Thomson Reuters)
At the time of writing (as on April 25, 2019, at 02:16 PM GMT), shares of NMC Health Plc were quoting at GBX 2,706 and added 21 points or 0.78% against its previous day close. Shares have registered a 52w high of GBX 4,376 and a 52w low of GBX 2,110. At the current market price, as quoted in the price chart, shares were trading 38.6% below the 52w high price and 27.20% above the 52w low price level.
From the simple moving average (SMA) standpoint, shares were trading above 30-day and 60-day simple moving average price by 7.71% and 3.36% respectively, but trading considerably below its 200-day SMA.
The outstanding market capitalisation of the company stood at around £5.5 bn with a dividend yield of 0.67%.                  Â
From the volume standpoint, the 5-day average daily volume traded on the London Stock Exchange was 29.17% below its 30-day average daily volume traded on the London Stock Exchange.
BlackRock Investment Management. LLC, Capital Research Global Investors and Aberdeen Standard Investment are the top institutional investors in the NMC Health PLC and all of them having stake above 4% in the company.
In the Financial year 2018, NMC Health Plc's reported revenue was $2,057.3 million in the financial year ending December 2018, against $1,603.4 million in the fiscal year 2017. There was an increase of 28.3 per cent due to the introduction of mandatory health insurance policy in Dubai, and all the divisions have shown significant growth as compared to the previous year.
NMC continues to be a strong growth story driven by a mix of organic initiatives and aggressive M&A activity.